.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Harvard Business School
Express Scripts
Federal Trade Commission
Teva
Julphar
Colorcon
Moodys
US Army
Citi

Generated: June 24, 2017

DrugPatentWatch Database Preview

TOPICORT Drug Profile

« Back to Dashboard

Which patents cover Topicort, and when can generic versions of Topicort launch?

Topicort is a drug marketed by Taro and is included in ten NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has four patent family members in four countries.

The generic ingredient in TOPICORT is desoximetasone. There are seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the desoximetasone profile page.

Summary for Tradename: TOPICORT

Patents:3
Applicants:1
NDAs:10
Suppliers / Packagers: see list3
Bulk Api Vendors: see list35
Clinical Trials: see list3
Patent Applications: see list4,065
Drug Prices:see details
DailyMed Link:TOPICORT at DailyMed

Pharmacology for Tradename: TOPICORT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro
TOPICORT
desoximetasone
GEL;TOPICAL074904-001Jul 14, 1998ABRXNoYes► Subscribe► Subscribe
Taro
TOPICORT
desoximetasone
OINTMENT;TOPICAL018763-001Sep 30, 1983DISCNYesNo► Subscribe► Subscribe
Taro
TOPICORT
desoximetasone
SPRAY;TOPICAL204141-001Apr 11, 2013ATRXYesYes8,715,624► SubscribeY ► Subscribe
Taro
TOPICORT LP
desoximetasone
CREAM;TOPICAL018309-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe
Taro
TOPICORT
desoximetasone
GEL;TOPICAL018586-001Mar 29, 1982DISCNYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TOPICORT

Drugname Dosage Strength RLD Submissiondate
desoximetasoneTopical Spray0.25%Topicort12/18/2013

Non-Orange Book Patents for Tradename: TOPICORT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,886,038 Composition and method for treatment of psoriasis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TOPICORT

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2006130510► Subscribe
European Patent Office1888026► Subscribe
Israel187666► Subscribe
Canada2609579► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
Cipla
Harvard Business School
Queensland Health
Medtronic
Novartis
Chubb
Cantor Fitzgerald
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot